135 results on '"Kalyanaraman, Vaniambadi"'
Search Results
2. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition
3. Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing
4. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research
5. Persistence of HIV-1 Structural Proteins and Glycoproteins in Lymph Nodes of Patients under Highly Active Antiretroviral Therapy
6. Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains
7. Unsung Hero Robert C. Gallo
8. Characterization of protective immune response elicited by a trimeric envelope protein from an Indian clade C HIV-1 isolate in rhesus macaques
9. Mapping of Neutralizing Antibody Epitopes on the Envelope of Viruses Obtained from Plasma Samples Exhibiting Broad Cross-Clade Neutralization Potential Against HIV-1
10. Human Immunodeficiency Virus Type 1 Envelope Glycoprotein gp120 Produces Immune Defects in CD4 + T Lymphocytes by Inhibiting Interleukin 2 mRNA
11. Monoclonal Antibodies against Human Immunodeficiency Virus (HIV) Type 2 Core Proteins: Cross-Reactivity with HIV Type 1 and Simian Immunodeficiency Virus
12. An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains
13. Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity
14. PRIMING OF RHESUS MACAQUES WITH ALVAC-HIV-1 VACCINES VIA SYSTEMIC ROUTE FOLLOWED BY BOOSTING WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) ENVELOPE PROTEIN CONTROLS VIRE- MIA IN SYSTEMIC AND MUCOSAL COMPARTMENTS AND PROTECTS FROM LOSS OF CD4+ T-CELLS FOL- LOWING CHALLENGE WITH PATHOGENIC SHIV ISO- LATES: ABSTRACT #39
15. Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains
16. A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: Potential impact on CTL epitopes
17. Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals
18. Epitope-Tagging Approach to Determine the Stoichiometry of the Structural and Nonstructural Proteins in the Virus Particles: Amount of Vpr in Relation to Gag in HIV-1
19. Extent of incorporation of HIV-1 Vpr into the virus particles is flexible and can be modulated by expression level in cells
20. Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition
21. DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant
22. Erratum: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition
23. Replicating Adenovirus-Simian Immunodeficiency Virus (SIV) Recombinant Priming and Envelope Protein Boosting Elicits Localized, Mucosal IgA Immunity in Rhesus Macaques Correlated with Delayed Acquisition following a Repeated Low-Dose Rectal SIVmac251 Challenge
24. Antigenicity and Immunogenicity of a Trimeric Envelope Protein from an Indian Clade C HIV-1 Isolate
25. Replicating Adenovirus-Simian Immunodeficiency Virus (SIV) Recombinant Priming and Envelope Protein Boosting Elicits Localized, Mucosal IgA Immunity in Rhesus Macaques Correlated with Delayed Acquisition following a Repeated Low-Dose Rectal SIV mac251 Challenge
26. Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains
27. Correlation of Vaccine-Elicited Systemic and Mucosal Nonneutralizing Antibody Activities with Reduced Acute Viremia following Intrarectal Simian Immunodeficiency Virus SIV mac251 Challenge of Rhesus Macaques
28. Correction: Human Immunodeficiency Virus Type 1 Envelope Glycoprotein gp120 Produces Immune Defects in CD4 + T Lymphocytes by Inhibiting Interleukin 2 mRNA
29. A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: Potential impact on CTL epitopes
30. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3
31. An Adenovirus-Based HIV Subtype B Prime/Boost Vaccine Regimen Elicits Antibodies Mediating Broad Antibody-Dependent Cellular Cytotoxicity Against Non-Subtype B HIV Strains
32. Evaluation of Passively Transferred, Nonneutralizing Antibody-Dependent Cellular Cytotoxicity-Mediating IgG in Protection of Neonatal Rhesus Macaques against Oral SIVmac251 Challenge
33. Subunit Recombinant Vaccine Protects against Monkeypox
34. Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4 + T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIV KU2 RNA Levels
35. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine
36. Functional Role of Residues Corresponding to Helical Domain II (Amino Acids 35 to 46) of Human Immunodeficiency Virus Type 1 Vpr
37. Neutralizing Antibodies from the Sera of Human Immunodeficiency Virus Type 1-Infected Individuals Bind to Monomeric gp120 and Oligomeric gp140
38. HIV-1 Neutralizing Antibodies in the Genital and Respiratory Tracts of Mice Intranasally Immunized with Oligomeric gp160
39. CD4 Cross-Linking (CD4XL) Induces RAS Activation and Tumor Necrosis Factor-α Secretion in CD4+ T Cells
40. Modulation of Bcl-2 Protein by CD4 Cross-Linking: A Possible Mechanism for Lymphocyte Apoptosis in Human Immunodeficiency Virus Infection and for Rescue of Apoptosis by Interleukin-2
41. HIV-1 gp120 Blocks Jacalin-Induced Proliferative Response in CD4+T Cells: Jacalin as a Useful Surrogate Marker for Qualitative and Quantitative Deficiency of CD4+T Cells in HIV-1 Infection1
42. HIV-1 gp160 Induces Transforming Growth Factor-β Production in Human PBMC
43. In vivo Induction of lnterleukin-1 Bioactivity in Brain Tissue after Intracerebral Infusion of Native gp120 and gp160
44. HIV-1 envelope glycoproteins induce activation of activated protein-1 in CD4+ T cells.
45. The HIV Glycoprotein gp160 Has Superantigen-like Properties
46. V?-Specific Activation of T-Cells by the HIV Glycoprotein gp160
47. HIV-1 gp160 as a Modifier of Th1 and Th2 Cytokine Response: gp160 Suppresses Interferon-γ and Interleukin-2 Production Concomitantly with Enhanced Interleukin-4 Production in Vitro
48. Envelope Glycoproteins of HIV-1 Interfere with T-Cell-Dependent B Cell Differentiation: Role of CD4-MHC Class II Interaction in the Effector Phase of T Cell Help
49. Biological characterization of noninfectious HIV-1 particles lacking the envelope protein
50. Misinterpretation of results of cytokine bioassays
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.